Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Average (2020 - 2025)

Historic Equity Average for Avidity Biosciences (RNA) over the last 6 years, with Q3 2025 value amounting to $1.5 billion.

  • Avidity Biosciences' Equity Average rose 1301.24% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 1301.24%. This contributed to the annual value of $962.9 million for FY2024, which is 7849.96% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Equity Average is $1.5 billion, which was up 1301.24% from $1.3 billion recorded in Q2 2025.
  • Avidity Biosciences' Equity Average's 5-year high stood at $1.5 billion during Q3 2025, with a 5-year trough of $275.3 million in Q2 2021.
  • In the last 5 years, Avidity Biosciences' Equity Average had a median value of $538.3 million in 2023 and averaged $724.5 million.
  • In the last 5 years, Avidity Biosciences' Equity Average surged by 136.78% in 2021 and then skyrocketed by 18759.05% in 2024.
  • Over the past 5 years, Avidity Biosciences' Equity Average (Quarter) stood at $388.2 million in 2021, then rose by 23.03% to $477.5 million in 2022, then rose by 6.61% to $509.1 million in 2023, then surged by 187.59% to $1.5 billion in 2024, then grew by 5.14% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.4 billion during Q1 2025.